Wellesley, Mass. – According to a new technical market
research report, NANOTECHNOLOGY IN MEDICAL APPLICATIONS: THE GLOBAL MARKET
(HLC069B) from BCC
Research (www.bccresearch.com),
nanomedical global sales totaled $72.8 billion in 2011 and are expected to
increase to $130.9 billion in 2016, a five-year compound annual growth rate
(CAGR) of 12.5%.
The market for nanotechnology used in medicine can be broken
down into six segments by therapeutic application: cardiovascular, anti-inflammatories,
anti-infectives, central nervous system (CNS) products, anticancers, and other
applications.
- The cardiovascular segment of the market, worth $4 billion
in 2011, is expected to increase at a CAGR of 16.5% to reach $8.6 billion in
2016. - The anti-inflammatories segment of the market, worth $7.3
billion in 2011, is expected to increase at a CAGR of 15.2% to reach $14.8
billion in 2016. - The anti-infectives segment was valued at $9.3 billion in
2011 and, by 2016, that value should reach $14.8 billion, a CAGR of 9.7%. - The CNS products segment was valued at $14 billion in 2011
and, by 2016, that value should reach $29.5 billion, a CAGR of 16.1%. - The largest segment, comprised of anti-cancers, was worth
$28 billion in 2011, and after increasing at a CAGR of 10.8%, should be worth
$46.7 billion in 2016. - The segment made up of other applications was worth $10.2
billion in 2011, and in 2016 should be worth $16.5 billion, a CAGR of 10.1%.
Nanomedicine is already an established market. Unlike some
other potential applications of nanotechnology, which are still largely
experimental, nanomedicine already has produced a number of significant
products in which the nano dimension has made a significant contribution to
product effectiveness. Now that aspects of the nanomedicine market are
established, it is appropriate to review the technology, see its practical
applications so far, evaluate the participating companies, and look to its
future.
In the field of nanomedicine research, the United States
accounts for one-third of all publications and half of patent filings. A
comparison between Europe as a whole and the United
States shows that, while Europe is at the forefront of
research, the United States
leads in the number of patent filings. The strong patenting activity of U.S. scientists
and companies indicates a more advanced commercialization status than
elsewhere.
This report is designed to satisfy the information needs of
a wide variety of individuals involved in the pharmaceutical marketplace,
including company senior management executives seeking to base their strategic
decisions on the best available information on market forces and trends. It
also is aimed, however, at managers and executives in marketing, research,
planning and sales departments who need readable, comprehensive, and up-to-date
background on the marketplace in which they are operating.
